Key result
Empagliflozin did not change NT-proBNP levels compared to placebo over 12 weeks in patients with mildly symptomatic HFrEF.
Why the study?
The study was conducted to investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on NT-proBNP in patients with heart failure and reduced ejection fraction.
Does empagliflozin 10 mg once daily reduce NT-proBNP in patients with mildly symptomatic HFrEF on recommended HF therapy?
RCT (n=190)
double-blinded
randomized
Yes
Does empagliflozin 10 mg once daily reduce NT-proBNP in patients with mildly symptomatic HFrEF on recommended HF therapy?
In low-risk patients with mildly symptomatic HFrEF, 12 weeks of empagliflozin treatment did not significantly change NT-proBNP levels, daily activity, or health status compared to placebo.
Answers are grounded in this paper and cite their sources.
Empagliflozin does not lower NT-proBNP in mildly symptomatic HFrEF; challenges expectations of short-term biomarker response on optimal therapy.
AIMS: To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) and reduced ejection fraction (HFrEF). METHODS AND RESULTS: Empire HF was an investigator-initiated, multi-center, double-blinded, placebo-controlled, randomized trial. Patients with mildly symptomatic HFrEF, mean (standard deviation (SD)) age 64 (11) years, 85% male, and mean left ventricular ejection fraction 29% (8), on recommended HF therapy were assigned to receive either empagliflozin 10 mg once daily or placebo for 12 weeks. The primary endpoint was the between-group difference in the change of NT-proBNP from baseline to 12 weeks. In total, 95 patients were assigned to empagliflozin and 95 to placebo. No significant difference in the change of NT-proBNP with empagliflozin versus placebo was observed [Empagliflozin: baseline, median (interquartile range (IQR)) 582 (304-1020) pg/mL, 12 weeks, 478 (281-961) pg/mL; Placebo: baseline, 605 (322-1070) pg/mL, 12 weeks, 520 (267-1075) pg/mL, adjusted ratio of change empagliflozin/placebo 0.98; 95% confidence interval (CI) 0.82-1.11, P = 0.7]. Further, no significant difference was observed in accelerometer-measured daily activity level [adjusted mean difference of change, empagliflozin versus placebo, -26.0 accelerometer counts; 95% CI -88.0 to 36.0, P = 0.4] or Kansas City Cardiomyopathy Questionnaire Overall Summary Score [adjusted mean difference of change, empagliflozin versus placebo 0.8; 95% CI -2.3 to 3.9, P = 0.6]. CONCLUSION: In low-risk patients with HFrEF with mild symptoms and on recommended HF therapy, empagliflozin did not change NT-proBNP after 12 weeks. Further, no change in daily activity level or health status was observed.
No takes yet. Share an insight, caveat, or question.
Jensen et al. (2020) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) (n=190). Empagliflozin vs. Placebo was evaluated on Between-group difference in the change of NT-proBNP from baseline to 12 weeks (adjusted ratio of change 0.98, 95% CI 0.82-1.11, p=0.7). Empagliflozin did not change NT-proBNP levels compared to placebo over 12 weeks in patients with mildly symptomatic HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: